|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-3-26
|
|
pubmed:abstractText |
To assess whether short-course total androgen blockade vs. a luteinizing hormone-releasing hormone (LHRH) agonist alone affects the risk of prostate cancer-specific mortality (PCSM) in men with localized but high-risk disease treated with radiotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1439-44
|
|
pubmed:meshHeading |
pubmed-meshheading:19540066-Aged,
pubmed-meshheading:19540066-Androgen Antagonists,
pubmed-meshheading:19540066-Antineoplastic Agents, Hormonal,
pubmed-meshheading:19540066-Drug Therapy, Combination,
pubmed-meshheading:19540066-Follow-Up Studies,
pubmed-meshheading:19540066-Goserelin,
pubmed-meshheading:19540066-Humans,
pubmed-meshheading:19540066-Leuprolide,
pubmed-meshheading:19540066-Male,
pubmed-meshheading:19540066-Multivariate Analysis,
pubmed-meshheading:19540066-Neoplasm Staging,
pubmed-meshheading:19540066-Prostate-Specific Antigen,
pubmed-meshheading:19540066-Prostatic Neoplasms,
pubmed-meshheading:19540066-Radiotherapy Dosage,
pubmed-meshheading:19540066-Regression Analysis
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
|
|
pubmed:affiliation |
Harvard Radiation Oncology Program, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA 02115, USA. ananda@partners.org
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
